Mindset Pharma Inc. announced that the United States Patent and Trademark Office (USPTO) has granted allowance for Mindset's patent application number 17/833,341, titled Psilocin Derivatives As Serotonergic Psychedelic Agents for the Treatment of CNS Disorders. Included within this application is MSP-1014, its backup MSP-1009, as well as additional prodrug candidates that the company classifies as belonging to Family 1. MSP-1014 and MSP-1009 are novel analogues of psilocybin that demonstrated improved efficacy and safety profiles, with reduced potential side effects and evidence of increased target engagement, in pre- clinical studies. Also included in this patent application are multiple other tryptamine prodrug candidates and other psilocybin analogs.

This application is one of a family of applications having a priority date of February 4, 2020.